Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy

Background The current therapeutic antibodies and chimeric antigen receptor (CAR) T cells are capable of recognizing surface antigens, but not of intracellular proteins, thus limiting the target coverage for drug development. To mimic the feature of T-cell receptor (TCR) that recognizes the complex...

Full description

Saved in:
Bibliographic Details
Main Authors: Xin Liu, Yang Du, Ningyan Zhang, Zhiqiang An, Wei Xiong, Yixiang Xu, Bingnan Yin, Yuqian Huang, Junjun Chu, Changsheng Xing, Chen Qian, Tianhao Duan, Helen Y Wang, John S. Yu, Rongfu Wang
Format: Article
Language:English
Published: BMJ Publishing Group 2022-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/3/e004035.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/10/3/e004035.full

Similar Items